H Moatti

1PUBLICATIONS
1CO-AUTHORS
Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Dec 28, 2024
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma.

H Moatti, P Brice, M-C Laroque

Pageof 1

Frequent Collaborators

1 joint publications

L Renaud